Abstract: Cancer still remains one of the leading causes of death worldwide. In spite of significant advances in treatment options and the advent of novel targeted therapies, there still remains an unmet need for the identification of novel pharmacological agents for cancer therapy. This has led to several studies evaluating the possible application of natural agents found in vegetables, fruits, or plant-derived products that may be useful for cancer treatment. Bergamottin is a furanocoumarin derived from grapefruits and is also a well-known cytochrome P450 inhibitor. Recent studies have demonstrated potent anti-oxidative, anti-inflammatory, and anti-cancer properties of grapefruit furanocoumarin both in vitro and in vivo. The present review focuses on the potential anti-neoplastic effects of bergamottin in different tumor models and briefly describes the molecular targets affected by this agent.

Keywords: bergamottin; cancer; chemoprevention; phytochemicals

1. Introduction

There has been considerable interest in the use of dietary compounds for various cancer prevention and therapy approaches [1–16]. Furanocoumarins are natural plant constituents present in many types of plants belonging to the Rutaceae and Umbelliferae families. Generally, furanocoumarins are primarily known to act as plants’ defense mechanism against predators and are regarded as natural pesticides [17,18]. Bergamottin is a major furanocoumarin and a bioactive component of grapefruits (Citrus paradisi) and other citrus fruits [19]. It was originally found in the oil of bergamot (Citrus bergamia), from which its name has been derived [20]. It acts as an inhibitor of some isoforms of the cytochrome P450 (CYP) enzyme, particularly CYP3A4 [21,22]. Bergamottin is also able to suppress the activities of CYP1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in human liver microsomes [21]. For this reason, it has been recommended that patients should preferably avoid the consumption of grapefruit or grapefruit juice when they are taking prescribed medications such as statins, antihistamines, and several other orally administered drugs. The consumption of a single 6-oz glass of grapefruit juice can cause the maximal effect with enhanced bioavailability observed up to 24 h after the administration [23]. These drug interactions are often referred to as the “grapefruit effect” and can lead to increased concentrations of the affected drugs in the bloodstream, which increases the
risk of potentially serious side effects from the drugs [20,24–27]. Bergamottin and the chemically related compound 6′,7′-dihydroxybergamottin are found to be responsible for this effect [20]. However, recent studies have also explored the potential benefits of CYP enzyme inhibition [28], and thus bergamottin may also be developed as an agent that can be targeted to increase the oral bioavailability of other pharmacological drugs [29]. Many studies have also demonstrated that grapefruit juice can augment the bioavailability of drugs that are CYP3A4 substrates [20,30], whereas no significant alterations were found for some other drugs [31,32]. It can exhibit a variety of interactions with drugs, leading to a reduction in therapeutic efficacy and to an augmentation of adverse effects at the same time. A variety of mechanisms, including the involvement of P-glycoprotein present in intestinal epithelium, have been proposed to explain the possible interactions of grapefruit juice with different drugs [33]. Moreover, at high grapefruit juice concentrations, P-glycoprotein-regulated vinblastine efflux was inhibited [34], whereas at low concentrations, the pumping of P-glycoprotein substrates was enhanced [35,36]. However, among various reported interactions of drugs with grapefruit juice, only a few are clinically relevant, whereas others studies predominantly involve the use of large quantities of the juice, which can be easily avoided in real-life situations to prevent the harmful effects of such interactions [37].

Additionally, there are few reports about the possible interactions of anti-cancer agents with grapefruit juice [38], and these are briefly summarized in Table 1. For example, a study analyzing the interaction of grapefruit juice with etoposide in six patients reported an unexpected decrease of 26.2% in the area under the concentration–time curve (AUC) after oral treatment [39]. Another article, which evaluated the effect of the administration of grapefruit juice with nilotinib in 21 healthy individuals, reported a 60% increase in the maximum serum concentrations (C\text{max}) and a 29% increase in the AUC without a significant effect on the half-life. Moreover, no adverse effects were noted in this study [40]. In another study, the interaction of grapefruit juice with sunitinib was analyzed in eight patients, and its co-administration increased the bioavailability of sunitinib by 11% without any increase in toxicity [41]. Interestingly, Cohen and coworkers also analyzed the toxicity and pharmacokinetic profile of intermittently administered sirolimus in patients with advanced malignancies when sirolimus was co-administered with two different CYP3A inhibitors, including grapefruit juice. They found that the grapefruit juice increased the sirolimus AUC by approximately 350%, although different grapefruit formulations may differ in their interaction profile with prescription drugs depending upon the content of various furanocoumarins present in them [42]. On the contrary, Schubert et al. reported that grapefruit juice can increase the 48-hour AUC of estradiol (E\text{2}) by approximately 40% after a single oral dose of E\text{2} in ovariectomized women [43]. Weber et al. elaborated that grapefruit juice increased the C\text{max} of ethinylestradiol by 38% and the 24-hour AUC by 28% [44]. Furthermore, Monroe and coworkers analyzed in a multiethnic cohort study of 46,080 postmenopausal women with 1657 cases of breast cancer whether grapefruit consumption was associated with an increased risk of breast cancer. They found that the risk was 30% higher in women who consumed the equivalent of one quarter of a fresh grapefruit or more per day, although the potential effects of diverse interactions between long-term grapefruit consumption and serum hormone concentrations still remain unclear [45]. Overall, additional studies are needed to investigate the potential interactions of bergamottin with anti-cancer agents.
The present review illustrates the role of bergamottin in chemoprevention and its potential for cancer prevention and therapy.

The biosynthesis of bergamottin starts with the formation of its molecular weight is 338.4 g/mol. The biosynthesis pathway of bergamottin is the attachment of a geranyl pyrophosphate to the newly methylated bergapten to generate bergamottin (Figure 2).

Table 1. Reported interactions between grapefruit juice and selected anti-neoplastic drugs.

| Antineoplastic Drug | Metabolism          | Interaction                                      | Ref.    |
|---------------------|---------------------|--------------------------------------------------|---------|
| Etoposide           | Metabolized by CYP3A4 | Decrease etoposide exposure (area under the concentration time curve (AUC) 26.2% ↓) | [39]    |
|                     |                     | Increase nilotinib exposure (Cmax 60% ↑, AUC 29% ↑) |         |
|                     |                     | No increase in adverse events                     | [40]    |
| Sunitinib           | Metabolized by CYP3A4 | Increase sunitinib exposure (Cmax 10.9% ↑, AUC 11% ↑) | [41]    |
|                     |                     | No increase in toxicity                           |         |

Overall, the furanocoumarins can exhibit several pharmacological properties, including those of antioxidant, anti-inflammatory, and anti-cancer activities [19]. Recently, intensive interest has focused on the chemopreventive and anti-cancer potential of bergamottin. Bergamottin has demonstrated significant anti-cancer activity in skin, myeloma, leukemia, lung cancer, and other cancer cells. The present review illustrates the role of bergamottin in chemoprevention and its potential for cancer prevention and therapy.

2. Chemical Properties of Bergamottin

Furanocoumarins consists of a furan ring fused with coumarin and subdivided into the linear or psoralen type and the angular or angelicin type. In the linear furanocoumarins, the furan ring is connected to the benzopyrone in the carbon 6 and 7 positions, whereas the angular furanocoumarins have it fused in the carbon 7 and 8 positions (Figure 1). Its elementary composition is C_{21}H_{22}O_{4} and its molecular weight is 338.4 g/mol.

![Bergamottin](image)

**Figure 1.** The chemical structure of bergamottin.

Umbelliferone is often regarded as the parent of the more complex furanocoumarins, both structurally and biogenetically. The biosynthesis of bergamottin starts with the formation of demethylsuberosin, which is formed via the alkylation of umbelliferone [46]. Demethylsuberosin is transformed into marmesin by the CYP monoxygenase catalyst in the presence of NADPH and oxygen [47]. This process is then repeated to remove the hydroxyisopropyl substituent from marmesin to form psoralen and then to add a hydroxyl group at the 5-position to form bergaptol [48]. Bergaptol is next methylated with S-adenosyl methionine to form bergapten. The final step in this biosynthesis is the attachment of a geranyl pyrophosphate to the newly methylated bergapten to generate bergamottin (Figure 2).
demonstrated significant anti-cancer activity in skin, myeloma, leukemia, lung cancer, and other cancer cells. The present review illustrates the role of bergamottin in chemoprevention and its potential for cancer prevention and therapy.

2. Chemical Properties of Bergamottin

Furanocoumarins consists of a furan ring fused with coumarin and subdivided into the linear or psoralen type and the angular or angelicin type. In the linear furanocoumarins, the furan ring is connected to the benzo pyrone in the carbon 6 and 7 positions, whereas the angular furanocoumarins have it fused in the carbon 7 and 8 positions (Figure 1). Its elementary composition is \( \text{C}_{21}\text{H}_{22}\text{O}_{4} \) and its molecular weight is 338.4 g/mol.

Figure 1. The chemical structure of bergamottin.

Umbelliferone is often regarded as the parent of the more complex furanocoumarins, both structurally and biogenetically. The biosynthesis of bergamottin starts with the formation of demethylsuberosin, which is formed via the alkylation of umbelliferone [46]. Demethylsuberosin is transformed into marmesin by the CYP monooxygenase catalyst in the presence of NADPH and oxygen [47]. This process is then repeated to remove the hydroxyisopropyl substituent from marmesin to form psoralen and then to add a hydroxyl group at the 5-position to form bergaptol [48]. Bergaptol is next methylated with S-adenosyl methionine to form bergapten. The final step in this biosynthesis is the attachment of a geranyl pyrophosphate to the newly methylated bergapten to generate bergamottin (Figure 2).

Figure 2. Biosynthesis pathway of bergamottin.

3. Metabolism of Bergamottin

There are various prior reports that have highlighted the metabolic profile of furocoumarins [49]. In a pharmacokinetic study in humans, the \( C_{\text{max}} \) values after the administration of 6 and 12 mg bergamottin were 2.1 and 5.9 ng/mL, respectively, and the times of peak concentrations (\( T_{\text{max}} \)) were 0.8 and 1.1 h, respectively. Interestingly, 6',7'-dihydroxybergamottin has been detected in the plasma of some individuals after exposure to bergamottin [50]. In a study to determine the concentrations of furanocoumarins in healthy young adults before and after the ingestion of grapefruit or grapefruit juice, bergamottin and 6',7'-dihydroxybergamottin were predominant compounds found in grapefruit flesh, juice, and plasma, while bergaptol and 6',7'-dihydroxybergamottin were major compounds detected in the urine [51,52].

It has been demonstrated that the metabolism of both bergamottin and the furan ring of the psoralen moiety by CYPs can result in the formation of reactive intermediates, thereby causing inhibition of the P450 enzyme, while the metabolism of the geranyloxy chain can produce stable metabolites [48]. The metabolism of bergamottin by CYP3A4, CYP3A5, and CYP2B6 has been investigated [48,53]. Interestingly, it was found that CYP2B6 metabolized bergamottin primarily to 5'-OH-bergamottin, 6'-OH-bergamottin, and 7'-OH-bergamottin as well as to one minor metabolite (bergaptol). Because 6'- and 7'-OH-bergamottin were the primary metabolites, it was suggested that CYP2B6 can preferentially oxidize the geranyloxy chain of bergamottin. The CYP3A5 metabolism of bergamottin can also generate three major metabolites, i.e., bergaptol, 5'-OH-bergamottin, and 2'-OH-bergamottin, as well as two minor metabolites, i.e., 6',7'-dihydroxybergamottin and 6'- and 7'-OH-bergamottin, whereas CYP3A5 and CYP2B6 induced the formation of bergamottin metabolites that can form active glutathione conjugates [48].
4. Bergamottin and Cancer

Exposure to furanocoumarins in large doses combined with ultraviolet radiation, such as through photochemotherapy, is known to induce skin tumorigenesis in both animals and humans. Recent epidemiological data suggest that relatively high levels of dietary exposure to furanocoumarins may also increase the risk of skin cancer [49]. In particular, psoralen, 5-methoxypsoralen (5-MOP), and 8-methoxypsoralen (8-MOP) are well known for their phototoxic, photomutagenic, and photocarcinogenic properties [54,55]. Recently, it has been shown that bergamottin does not exert any significant photomutagenicity on its own, as tested by a model of photomutagenicity of some furanocoumarins in V79 cells using 5-MOP as a reference compound [56]. Interestingly, the potential protective effects of furanocoumarins have also been studied in various cancer models. Table 2 briefly summarizes the potential effects of bergamottin against several cancer types and summarizes the biological mechanisms underlying its anti-neoplastic actions.

Table 2. In vitro and in vivo effects of bergamottin against malignancies.

| Type of Cancers | Cell Lines | Dose | Biological Effect | Ref. |
|----------------|------------|------|-------------------|------|
| **In Vitro**   |            |      |                   |      |
| Multiple myeloma | U266       | 50 and 100 µM for 24 h | Inhibits cell proliferation, induces apoptosis, and inhibits JAK/STAT3 activation | [57] |
| Leukemia       | HL-60      | 40 µM for 4 days, 6.25, 12.5, 25, and 50 µg/mL for 3 days | Inhibits cell proliferation | [58] |
|                | KBM-5      | 50 µM for 12 h in combination with 10 µM simvastatin | Combination with simvastatin exhibits synergistic effects of TNF-induced cytotoxicity and apoptosis | [60] |
| Skin cancer    | Mouse epidermal keratinocytes | 2 nM | Inhibits DNA adduct formation induced by B[a]P and DMBA | [61] |
| Lung cancer    | A549       | 10, 25, and 50 µM for 48 h | Induces apoptosis, cell cycle arrest, and loss of mitochondrial membrane potential | [62] |
|                | A549       | 100 µM for 24 h | Suppresses EMF, TGF-β-induced EMT, and cell invasive potential | [63] |
| Fibrosarcoma   | HT-1080    | 5, 25, and 50 µM for 24 h | Reduces PMA-induced MMP-9 and MMP-2 activation | [64] |
| Liver cancer   | HepG2      | 6.25, 12.5, 25, and 50 µg/mL for 3 days | Abrogates cell proliferation | [59] |
| Gastric cancer | BGC-823    | 6.25, 12.5, 25, and 50 µg/mL for 3 days | Inhibits cell proliferation | [59] |
| Breast cancer  | NCI-N87    | 4, 20, and 100 µM for 48 h | Attenuates cell proliferation | [65] |
|                | MDA-MB-231 | 100 µM for 6 h | Suppresses cell proliferation | [57] |
|                | MCF-7      | 100 µM for 24 h | Suppresses cell proliferation | [66] |
| Prostate cancer | DU145      | 100 µM for 6 h | Suppresses STAT3 activation | [57] |
| Neuroblastoma  | SH-SYSY    | BEO (0.01, 0.02, and 0.03%) for 24 h | Suppresses cell proliferation | [67] |
| Glioma         | U87, U251  | 2 and 10 µM for 48 h | Exhibits anti-invasive activity through the inactivation of Rac1 and the downregulation of MMP-9 | [68] |
| **In Vivo**    |            |      |                   |      |
| Skin cancer    | SENCAR mice (B[a]P) | 400 nmol; 5 min pretreatment | Suppresses B[a]P-induced tumor initiation | [69] |
| Lung cancer    | BALB/c nude mice xenograft model (A549) | 25, 50, and 100 mg/kg; daily; 18 days | Inhibits lung cancer growth | [62] |

Abbreviations: B[a]P: Benzo[a]pyrene; DMBA: 7,12-Dimethylbenz[a]anthracene; JAK/STAT3: Janus-activated kinases/Signal transducer and activator of transcription 3; TNF: Tumor necrosis factor; EMF: Epithelial-to-mesenchymal transition; TGF: Transforming growth factor; PMA: Phorbol 12-myristate 13-acetate; MMP: Matrix metalloproteinase.
4.1. Multiple Myeloma

Our group has investigated the anti-cancer potential of bergamottin in multiple myeloma (MM) cells [57]. In this study, bergamottin inhibited proliferation and induced apoptosis in human U266 MM cells through the downregulation of the signal transducer and activator of transcription 3 (STAT3) signaling pathway, which has been closely associated with tumorigenesis [70–80]. This suppression was mediated through the inhibition of phosphorylation of Janus-activated kinases (JAK) 1 and 2 and c-Src, as well as the induction of tyrosine phosphatase SHP-1. Furthermore, bergamottin caused a substantial down-modulation of the expression of various oncogenic proteins and significantly promoted the apoptotic effects of bortezomib and thalidomide, two drugs commonly used to treat MM. [57].

4.2. Leukemia

The anti-proliferative activity of bergamottin against promyelocytic leukemia HL-60 cells has also previously been reported by our group [58,59]. We observed that the combination of bergamottin and simvastatin produced synergistic effects on the tumor necrosis factor (TNF)-induced cytotoxicity and apoptosis in human chronic myelogenous leukemia KBM-5 cells. The anti-proliferative and pro-apoptotic effects of this combination therapy were found to be mediated through the suppression of the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB), a master transcription factor regulating tumor growth and survival [60,81–92].

4.3. Skin Cancer

Polycyclic aromatic hydrocarbons (PAHs) such as benzo[α]pyrene (B[α]P) and 7,12-dimethylbenz[a]anthracene (DMBA) are routinely employed to initiate skin cancer in mouse models [93]. Bergamottin has been reported to reduce the formation of water-soluble metabolites of B[α]P and to abrogate the binding of B[α]P to DNA. It also abrogated the formation of DNA adducts derived from the anti-diol-epoxide diastereomers from both B[α]P and DMBA [61]. In another study, bergamottin was analyzed for its potential effects on the formation of B[α]P and DMBA DNA adducts in mouse epidermis. Moreover, bergamottin was noted to significantly decrease the covalent binding of B[α]P to DNA in a dose-dependent fashion, but did not significantly affect the covalent binding of DMBA to epidermal DNA at two different concentrations [69].

Interestingly, Kleiner et al. reported that bergamottin can suppress the metabolism of DMBA to DMBA-3,4-diol and block DNA adduct formation in mouse hepatoma-derived 1c1c7 (Hepa-1) cells but had a relatively minimal effect in mouse embryo fibroblast C3H/10T1/2 (10T1/2) cells. The findings of this study also indicated that bergamottin can function as a more selective inhibitor of P450 1a1 but appeared to be less potent in blocking the metabolic activation of DMBA in mouse epidermis [94]. In another study by the same group, it was found that although bergamottin was not effective at blocking DMBA bioactivation in the mouse skin model, it could abrogate the bioactivation of both DMBA as well as B[α]P in breast cancer MCF-7 cells [66].

4.4. Lung Cancer

The anti-cancer properties of bergamottin were also evaluated in human non-small cell lung carcinoma A549 cells. The anti-cancer effects of bergamottin were linked to an inhibited activity of colony formation, cell invasion, and cell migration in A549 cells. Furthermore, bergamottin induced apoptosis and cell cycle arrest at the G2/M phase, and it caused a significant reduction in the mitochondrial membrane potential [62]. In the mouse xenograft model of A549 cells, bergamottin showed a significant decrease of the tumor volume and weight after 18 days of consecutive treatment [62]. In a recent study from our group, bergamottin was shown to exhibit an inhibitory effect on the epithelial-to-mesenchymal transition (EMT) process in lung cancer cells [63]. EMT can facilitate the transition from a sessile epithelial state to a motile, invasive mesenchymal state and thereby cause
the tumor cells to undergo metastasis to distant sites [95,96]. Interestingly, bergamottin was found to suppress transforming growth factor beta (TGF-β)-induced EMT and the cell invasive potential. This effect was found to be mediated by its inhibitory effect on PI3K, Akt, and mTOR kinases [63].

4.5. Fibrosarcoma

The inhibitory effects of bergamottin on metastasis and its possible mechanisms of action were also investigated in human fibrosarcoma HT-1080 cells [64]. Matrix metalloproteinases (MMPs) are actively involved in the metastasis of cancer cells, and the drug was found to substantially reduce the phorbol 12-myristate 13-acetate (PMA)-induced activation of MMP-9 and MMP-2 and to inhibit cell invasion and migration. Its anti-metastatic effects were mediated via the downregulation of NF-κB activation and the phosphorylation of p38 mitogen-activated protein kinase and c-Jun N-terminal kinase.

4.6. Other Cancers

The anti-proliferative activity of bergamottin against human liver cancer HepG2 cells and gastric cancer BGC-823 cells has also been reported [59]. The cytotoxic effect of bergamottin on gastric cancer NCI-N87 cells has also been reported [65]. Additionally, studies have indicated that citrus fruit intake may reduce the risk of gastric cancer [97–99]. Bergamottin inhibited the proliferation of human breast cancer MDA-MB-231 and prostate cancer DU145 cells [57]. In human neuroblastoma SH-SY5Y cells, bergamot essential oils (BEOs) were also found to exhibit significant anti-proliferative effects [67] and it was hypothesized that bergamottin and 5-geranyloxy-7-methoxycoumarin may have substantially contributed to the BEO-induced anti-proliferative effects. Bergamottin also exhibited anti-invasive activity in human glioma cells through the inactivation of Rac1 activity and the downregulation of MMP-9 [68].

In summary, several studies using animal models and different cancer cell lines provide substantial evidence that bergamottin has beneficial effects against a variety of cancers. These effects are mostly attributed to its ability to regulate several cancer-related pathways including chemical detoxification, cell cycle arrest, apoptosis, migration, invasion, and angiogenesis. Figure 3 provides a concise summary of the anti-cancer effects of bergamottin with possible underlying molecular mechanisms. Bergamottin appears to be a promising natural agent for cancer prevention and therapy, and its evaluation in human clinical trials is needed to investigate its possible anti-cancer applications either as a therapeutic agent or as adjuvant therapy.

Figure 3. Proposed mechanisms of the anti-cancer activity of bergamottin.
5. Conclusions

The anti-cancer activity of bergamottin has been reported against many types of cancers, as briefly summarized in this review. Bergamottin may be a suitable candidate for the development of novel agents for cancer prevention and therapy. Further studies should be undertaken to examine the pharmacokinetics, ideal dosage, long-term safety, and adverse effects of bergamottin.

Funding: This work was supported by a National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIP) (NRF-2016R1A6A3A11930941, 2017M3A9E4065333, and 2018R1D1A1B07042969).

Conflicts of Interest: The authors declare no conflicts of interest.

References

1. Deorukhkar, A.; Krishnan, S.; Sethi, G.; Aggarwal, B.B. Back to basics: How natural products can provide the basis for new therapeutics. *Expert Opin. Investig. Drugs* 2007, 16, 1753–1773. [CrossRef] [PubMed]
2. Yang, S.F.; Weng, C.J.; Sethi, G.; Hu, D.N. Natural bioactives and phytochemicals serve in cancer treatment and prevention. *Evid. Based Complement. Altern. Med.* 2013, 2013, 698190. [CrossRef] [PubMed]
3. Tang, C.H.; Sethi, G.; Kuo, P.L. Novel medicines and strategies in cancer treatment and prevention. *Biomed Res. Int.* 2014, 2014, 474078. [CrossRef] [PubMed]
4. Hsieh, Y.S.; Yang, S.F.; Sethi, G.; Hu, D.N. Natural bioactives in cancer treatment and prevention. *Biomed Res. Int.* 2015, 2015, 182835. [CrossRef] [PubMed]
5. Yarla, N.S.; Bishayee, A.; Sethi, G.; Reddanna, P.; Kalle, A.M.; Dhananjaya, B.L.; Dowluru, K.S.; Chintala, R.; Daddukuri, G.R. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. *Semin. Cancer Boil.* 2016, 40–41, 48–81. [CrossRef] [PubMed]
6. Hasanpourghadi, M.; Looi, C.Y.; Pandurangan, A.K.; Sethi, G.; Wong, W.F.; Mustafa, M.R. Phytometabolites Targeting the Warburg Effect in Cancer Cells: A Mechanistic Review. *Curr. Drug Targets* 2017, 18, 1086–1094. [CrossRef] [PubMed]
7. Shanmugam, M.K.; Warrier, S.; Kumar, A.P.; Sethi, G.; Arfuso, F. Potential Role of Natural Compounds as Anti-Angiogenic Agents in Cancer. *Curr. Vasc. Pharmacol.* 2017, 15, 503–519. [CrossRef] [PubMed]
8. Shanmugam, M.K.; Kannaiyan, R.; Sethi, G. Targeting cell signaling and apoptotic pathways by dietary agents: Role in the prevention and treatment of cancer. *Nutr. Cancer* 2011, 63, 161–173. [CrossRef]
9. Aggarwal, B.B.; Sethi, G.; Baladandayuthapani, V.; Krishnan, S.; Shishodia, S. Targeting cell signaling pathways for drug discovery: An old lock needs a new key. *J. Cell. Biochem.* 2007, 102, 580–592. [CrossRef]
10. Jung, Y.Y.; Hwang, S.T.; Sethi, G.; Fan, L.; Arfuso, F.; Ahn, K.S. Potential Anti-Inflammatory and Anti-Cancer Properties of Farnesol. *Molecules* 2018, 23, 2827. [CrossRef]
11. Merarchi, M.; Sethi, G.; Fan, L.; Mishra, S.; Arfuso, F.; Ahn, K.S. Molecular Targets Modulated by Fangchinoline in Tumor Cells and Preclinical Models. *Molecules* 2018, 23, 2538. [CrossRef] [PubMed]
12. Sethi, G.; Shanmugam, M.K.; Warrier, S.; Merarchi, M.; Arfuso, F.; Kumar, A.P.; Bishayee, A. Pro-Apoptotic and Anti-Cancer Properties of Diosgenin: A Comprehensive and Critical Review. *Nutrients* 2018, 10, 645. [CrossRef] [PubMed]
13. Ko, J.H.; Sethi, G.; Um, J.Y.; Shanmugam, M.K.; Arfuso, F.; Kumar, A.P.; Bishayee, A.; Ahn, K.S. The Role of Resveratrol in Cancer Therapy. *Int. J. Mol. Sci.* 2017, 18, 2589. [CrossRef] [PubMed]
14. Tewari, D.; Nabavi, S.F.; Nabavi, S.M.; Sureda, A.; Farooqi, A.A.; Atanasov, A.G.; Vacca, R.A.; Sethi, G.; Bishayee, A. Targeting activator protein 1 signaling pathway by bioactive natural agents: Possible therapeutic strategy for cancer prevention and intervention. *Pharmacol. Res.* 2018, 128, 366–375. [CrossRef] [PubMed]
15. Bishayee, A.; Sethi, G. Bioactive natural products in cancer prevention and therapy: Progress and promise. *Semin. Cancer Boil.* 2016, 40–41, 1–3. [CrossRef] [PubMed]
16. Shanmugam, M.K.; Lee, J.H.; Chai, E.Z.; Kanchi, M.M.; Kar, S.; Arfuso, F.; Dharmarajan, A.; Kumar, A.P.; Ramar, P.S.; Looi, C.Y.; et al. Cancer prevention and therapy through the modulation of transcription factors by bioactive natural compounds. *Semin. Cancer Boil.* 2016, 40–41, 35–47. [CrossRef]
17. Wägstaff, D.J. Dietary exposure to furocoumarins. *Regul. Toxicol. Pharmacol. RTP* 1991, 14, 261–272. [CrossRef]
18. Dolan, L.C.; Matulka, R.A.; Burdock, G.A. Naturally occurring food toxins. *Toxins* 2010, 2, 2289–2332. [CrossRef]
19. hung, w.l.; suh, j.h.; wang, y. chemistry and health effects of furanocoumarins in grapefruit. j. food drug anal. 2017, 25, 71–83. [crossref]

20. bailey, d.g.; malcolm, j.; arnold, o.; spence, j.d. grapefruit juice-drug interactions. br. j. clin. pharmacol. 1998, 46, 101–110. [crossref]

21. he, k.; iyer, k.r.; hayes, r.n.; sinz, m.w.; woolf, t.f.; hollenberg, p.f. inactivation of cytochrome p450 3a4 by bergamottin, a component of grapefruit juice. chem. res. toxicol. 1998, 11, 252–259. [crossref]

22. girennavar, b.; poulose, s.m.; jayaprakasha, g.k.; bhat, n.g.; patil, b.s. furanocoumarins from grapefruit juice and their effect on human cyp 3a4 and cyp 1b1 isoenzymes. biorg. med. chem. 2006, 14, 2606–2612. [crossref]

23. monroe, k.r.; stanczyk, f.z.; besinque, k.h.; pike, m.c. the effect of grapefruit intake on endogenous serum estrogen levels in postmenopausal women. nutr. cancer 2013, 65, 644–652. [crossref]

24. kantola, t.; kivisto, k.t.; neuvonen, p.j. grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. clin. pharmacol. ther. 1998, 63, 397–402. [crossref]

25. lilja, j.j.; kivisto, k.t.; neuvonen, p.j. grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and hmg-coa reductase inhibitors. clin. pharmacol. ther. 1998, 64, 477–483. [crossref]

26. benton, r.e.; honig, p.k.; zamani, k.; cantilena, l.r.; woosley, r.l. grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. clin. pharmacol. ther. 1996, 59, 383–388. [crossref]

27. lundahl, j.u.; regardh, c.g.; edgar, b.; johnsson, g. the interaction effect of grapefruit juice is maximal after the first glass. eur. j. clin. pharmacol. 1998, 54, 75–81. [crossref]

28. row, e.c.; brown, s.a.; stachulski, a.v.; lennard, m.s. design, synthesis and evaluation of furanocoumarin monomers as inhibitors of cyp3a4. org. biol. chem. 2006, 4, 1604–1610. [crossref]

29. christensen, h.; asberg, a.; holmboe, a.b.; berg, k.j. coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. eur. j. clin. pharmacol. 2002, 58, 515–520. [crossref]

30. kane, g.c.; lipsky, j.i. drug-grapefruit juice interactions. mayo clin. proc. 2000, 75, 933–942. [crossref]

31. cheng, k.l.; nafziger, a.n.; pelouquin, c.a.; axsden, g.w. effect of grapefruit juice on clarithromycin pharmacokinetics. antimiicrob. agents chemother. 1998, 42, 927–929. [crossref]

32. ho, p.c.; chalcroft, s.c.; coville, p.f.; wanwimolruk, s. grapefruit juice has no effect on quinine pharmacokinetics. eur. j. clin. pharmacol. 1999, 55, 393–398. [crossref]

33. hall, s.d.; thummel, k.e.; watkins, p.b.; lown, k.s.; benet, l.z.; paine, m.f.; mayo, r.r.; turgeon, d.k.; bailey, d.g.; fontana, r.j.; et al. molecular and physical mechanisms of first-pass extraction. drug metab. dispos. boil. fate chem. 1999, 27, 161–166.

34. takanaga, h.; ohnishi, a.; matsuo, h.; sawada, y. inhibition of vinblastine efflux mediated by p-glycoprotein by grapefruit juice components in caco-2 cells. boil. pharm. bull. 1998, 21, 1062–1066. [crossref]

35. soldner, a.; christians, u.; susanto, m.; wacher, v.j.; silverman, j.a.; benet, l.z. grapefruit juice activates p-glycoprotein-mediated drug transport. pharm. res. 1999, 16, 478–485. [crossref]

36. kobayashi, k.r.m.j.; fleming, g.f.; vogelzang, n.j.; cooper, n.; sun, b.l. a phase i study of cyp3a4 modulation of oral (po) etoposide with ketoconazole (kcz) in patients (pts) with advanced cancer (ca). proc. am. j. clin. oncol. 1996, 15, 471.

37. hanley, m.j.; cancalon, p.; widmer, w.w.; greenblatt, d.j. the effect of grapefruit juice on drug disposition. expert opin. drug metab. toxicol. 2011, 7, 267–286. [crossref]

38. collado-borrell, r.; escudero-vilaplana, v.; romero-jimenez, r.; iglesias-peinado, i.; herranz-alonso, a.; sanjurjo-saez, m. oral antimicrobial agent interactions with medicinal plants and food: an issue to take into account. j. cancer res. clin. oncol. 2016, 142, 2319–2330. [crossref]

39. reif, s.; nicolson, m.c.; bisset, d.; reid, m.; kloft, c.; jaehde, u.; mcleod, h.l. effect of grapefruit juice intake on etoposide bioavailability. eur. j. clin. pharmacol. 2002, 58, 491–494. [crossref]

40. yin, o.q.; gallagher, n.; li, a.; zhou, w.; harrell, r.; schran, h. effect of grapefruit juice on the pharmacokinetics of nilotinib in healthy participants. j. clin. pharmacol. 2010, 50, 188–194. [crossref]

41. van erp, n.p.; baker, s.d.; zandvliet, a.s.; ploeger, b.a.; den hollander, m.; chen, z.; den hartigh, j.; konig-quartel, j.m.; guchelaar, h.j.; gelderblom, h. marginal increase of sunitinib exposure by grapefruit juice. cancer chemother. pharmacol. 2011, 695–703. [crossref]
42. Cohen, E.E.; Wu, K.; Hartford, C.; Kocherginsky, M.; Eaton, K.N.; Zha, Y.; Nallari, A.; Maitland, M.L.; Fox-Kay, K.; Mosher, K.; et al. Phase I studies of sirolimus alone or in combination with pharmacokinetic modulators in advanced cancer patients. *Clin. Cancer Res.* 2012, 18, 4785–4793. [CrossRef]

43. Schubert, W.; Cullberg, G.; Edgard, B.; Hedner, T. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. *Maturitas* 1994, 20, 155–163. [CrossRef]

44. Weber, A.; Jager, R.; Borner, A.; Klinger, G.; Vollanth, R.; Matthey, K.; Balogh, A. Can grapefruit juice influence ethinylestradiol bioavailability? *Contraception* 1996, 53, 41–47. [CrossRef]

45. Monroe, K.R.; Murphy, S.P.; Kolonel, L.N.; Pike, M.C. Prospective study of grapefruit intake and risk of breast cancer in postmenopausal women: The Multiethnic Cohort Study. *Br. J. Cancer* 2007, 97, 440–445. [CrossRef]

46. Bisagni, E. Synthesis of psoralens and analogues. *J. Photochem. Photobiol. Bbiol.* 1992, 14, 23–46. [CrossRef]

47. Voznesensky, A.I.; Schenkman, J.B. The cytochrome P450 2B4-NADPH cytochrome P450 reductase electron transfer complex is not formed by charge-pairing. *J. Biol. Chem.* 1992, 267, 14669–14676.

48. Kent, U.M.; Lin, H.L.; Noon, K.R.; Harris, D.L.; Hollenberg, P.F. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5. *J. Pharmacol. Exp. Ther.* 2006, 318, 992–1005. [CrossRef]

50. Goosen, T.C.; Cillie, D.; Bailey, D.G.; Yu, C.; He, K.; Hollenberg, P.F.; Woster, P.M.; Cohen, L.; Williams, J.A.; Rheeders, M.; et al. Bergamottin contribution to the grapefruit juice-felodipine interaction and disposition in humans. *Clin. Pharmacol. Ther.* 2004, 76, 607–617. [CrossRef]

53. Lin, H.L.; Kent, U.M.; Hollenberg, P.F. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: Evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. *J. Pharmacol. Exp. Ther.* 2005, 313, 154–164. [CrossRef]

55. Papadopoulo, D.; Moustacchi, E. Mutagenic effects photoinduced in normal human lymphoblasts by a monofunctional pyridopsoralen in comparison to 8-methoxypsoralen. *Mutat. Res.* 1990, 245, 259–266. [CrossRef]

57. Kim, S.M.; Lee, J.H.; Sethi, G.; Kim, C.; Baek, S.H.; Nam, D.; Chung, W.S.; Kim, S.H.; Shim, B.S.; Ahn, K.S. Bergamottin, a natural furanocoumarin obtained from grapefruit juice induces chemosensitization and apoptosis through the inhibition of STAT3 signaling pathway in tumor cells. *Cancer Lett.* 2014, 354, 153–163. [CrossRef]

58. Kawai, S.; Tomono, Y.; Katase, E.; Ogawa, K.; Yano, M. Isolation of furanocoumarins from bergamot fruits as HL-60 differentiation-inducing compounds. *J. Agric. Food Chem.* 1999, 47, 4073–4078. [CrossRef]

59. Liu, Y.; Ren, C.; Cao, Y.; Wang, Y.; Duan, W.; Xie, L.; Sun, C.; Li, X. Characterization and Purification of Bergamottin from *Citrus grandis* (L.) Osbeck cv. Yongjiazaoxiangyou and Its Antiproliferative Activity and Effect on Glucose Consumption in HepG2 cells. *Molecules* 2017, 22, 1227. [CrossRef]

60. Kim, S.M.; Lee, E.J.; Lee, J.H.; Yang, W.M.; Nam, D.; Lee, J.H.; Lee, S.G.; Um, J.Y.; Shim, B.S.; Ahn, K.S. Simvastatin in combination with bergamottin potentiates TNF-induced apoptosis through modulation of NF-kappaB signalling pathway in human chronic myelogenous leukaemia. *Pharm. Boil.* 2016, 54, 2050–2060. [CrossRef]
61. Cai, Y.; Baer-Dubowska, W.; Ashwood-Smith, M.; DiGiovanni, J. Inhibitory effects of naturally occurring coumarins on the metabolic activation of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in cultured mouse keratinocytes. *Carcinogenesis* **1997**, *18*, 215–222. [CrossRef] [PubMed]

62. Wu, H.J.; Wu, H.B.; Zhao, Y.Q.; Chen, L.J.; Zu, H.Z. Bergamottin isolated from Citrus bergamia exerts in vitro and in vivo antitumor activity in lung adenocarcinoma through the induction of apoptosis, cell cycle arrest, mitochondrial membrane potential loss and inhibition of cell migration and invasion. *Oncol. Rep.* **2016**, *36*, 324–332. [CrossRef] [PubMed]

63. Ko, J.H.; Nam, D.; Um, J.Y.; Jung, S.H.; Sethi, G.; Ahn, K.S. Bergamottin Suppresses Metastasis of Lung Cancer Cells through Abrogation of Diverse Oncogenic Signaling Cascades and Epithelial-to-Mesenchymal Transition. *Molecules* **2018**, *23*, 1601. [CrossRef] [PubMed]

64. Hwang, Y.P.; Yun, H.J.; Choi, H.W.; Jeong, H.G. Suppression of phorbol-12-myristate-13-acetate-induced tumor cell invasion by bergamottin via the inhibition of protein kinase Cdelta/p38 mitogen-activated protein kinase and JNK/nuclear factor-kappaB-dependent matrix metalloproteinase-9 expression. *Mol. Nutr. Food Res.* **2010**, *54*, 977–990. [CrossRef] [PubMed]

65. Sekiguchi, H.; Washida, K.; Murakami, A. Suppressive Effects of Selected Food Phytochemicals on CD74. *Int. J. Mol. Sci.* **2018**, 19, 4048. [CrossRef] [PubMed]

66. Kleiner, H.E.; Reed, M.J.; DiGiovanni, J. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene DNA adduct formation in MCF-7 cells. *Chem. Res. Toxicol.* **2003**, *16*, 415–422. [CrossRef]

67. Navarra, M.; Ferlazzo, N.; Cirmi, S.; Trapasso, E.; Bramanti, P.; Lombardo, G.E.; Minciullo, P.L.; Calapai, G.; Gangemi, S. Effects of bergamot essential oil and its extractive fractions on SH-SY5Y human neuroblastoma cell growth. *J. Pharm. Pharmacol.* **2018**, *67*, 1042–1053. [CrossRef]

68. Luo, W.; Song, Z.; Sun, H.; Liang, J.; Zhao, S. Bergamottin, a natural furanocoumarin abundantly present in grapefruit juice, suppresses the invasiveness of human glioma cells via inactivation of Rac1 signaling. *Oncol. Lett.* **2018**, *15*, 3259–3266. [CrossRef]

69. Cai, Y.; Kleiner, H.; Johnston, D.; Dubowsky, A.; Bostic, S.; Ivie, W.; DiGiovanni, J. Effect of naturally occurring coumarins on the formation of epidermal DNA adducts and skin tumors induced by benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene in SENCAR mice. *Carcinogenesis* **1997**, *18*, 1521–1527. [CrossRef]

70. Arora, L.; Kumar, A.P.; Arfuso, F.; Chng, W.J.; Sethi, G. The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies. *Cancers* **2018**, *10*, 327. [CrossRef]

71. Lee, J.H.; Kim, C.; Lee, S.G.; Sethi, G.; Ahn, K.S. Ophiopogonin D, a Steroidal Glycoside Abrogates STAT3 Signaling Cascade and Exhibits Anti-Cancer Activity by Causing GSH/GSSG Imbalance in Lung Carcinoma. *Cancers* **2018**, *10*, 427. [CrossRef] [PubMed]

72. Wong, A.L.A.; Hirpara, J.L.; Pervaiz, S.; Eu, J.Q.; Sethi, G.; Goh, B.C. Do STAT3 inhibitors have potential in the future for cancer therapy? *Expert Opin. Investig. Drugs* **2017**, *26*, 883–887. [CrossRef] [PubMed]

73. Lee, J.H.; Kim, C.; Baek, S.H.; Ko, J.H.; Lee, S.G.; Yang, W.M.; Um, J.Y.; Sethi, G.; Ahn, K.S. Capsazepine inhibits JAK/STAT3 signaling, tumor growth, and cell survival in prostate cancer. *Oncotarget* **2017**, *8*, 17700–17711. [CrossRef] [PubMed]

74. Zhang, J.; Ahn, K.S.; Kim, C.; Shanmmugam, M.K.; Siveen, K.S.; Arfuso, F.; Samym, R.P.; Deivasigamanim, A.; Lim, L.H.; Wang, L.; et al. Nimbolide-Induced Oxidative Stress Abrogates STAT3 Signaling Cascade and Inhibits Tumor Growth in Transgenic Adenocarcinoma of Mouse Prostate Model. *Antioxid. Redox Signal.* **2016**, *24*, 575–589. [CrossRef] [PubMed]

75. Chai, E.Z.; Shanmmugam, M.K.; Arfuso, F.; Dharmarajan, A.; Wang, C.; Kumar, A.P.; Samym, R.P.; Lim, L.H.; Wang, L.; Goh, B.C.; et al. Targeting transcription factor STAT3 for cancer prevention and therapy. *Pharmcol. Ther.* **2016**, *162*, 86–97. [CrossRef] [PubMed]

76. Siveen, K.S.; Sikka, S.; Surana, R.; Dai, X.; Zhang, J.; Kumar, A.P.; Tan, B.K.; Sethi, G.; Bishayee, A. Targeting the STAT3 signaling pathway in cancer: Role of synthetic and natural inhibitors. *Biochim. Biophys. Acta* **2014**, *1845*, 136–154. [CrossRef] [PubMed]

77. Subramaniam, A.; Shanmmugam, M.K.; Ong, T.H.; Li, F.; Perumal, E.; Chen, L.; Vali, S.; Abbasi, T.; Kapoor, S.; Ahn, K.S.; et al. Emodin inhibits growth and induces apoptosis in an orthotopic hepatocellular carcinoma model by blocking activation of STAT3. *Br. J. Pharmacol.* **2013**, *170*, 807–821. [CrossRef]
78. Subramaniam, A.; Shanmugam, M.K.; Perumal, E.; Li, F.; Nachiyappan, A.; Dai, X.; Swamy, S.N.; Ahn, K.S.; Kumar, A.P.; Tan, B.K.; et al. Potential role of signal transducer and activator of transcription (STAT)3 signaling pathway in inflammation, survival, proliferation and invasion of hepatocellular carcinoma. *Biochim. Biophys. Acta* 2013, 1835, 46–60. [CrossRef]

79. Jung, Y.Y.; Lee, J.H.; Nam, D.; Narula, A.S.; Namjoshi, O.A.; Blough, B.E.; Um, J.Y.; Sethi, G.; Ahn, K.S. Anti-myeloma Effects of Icariin Are Mediated Through the Attenuation of JAK/STAT3-Dependent Signaling Cascade. *Front. Pharmacol.* 2018, 9, 531. [CrossRef]

80. Kim, C.; Lee, S.G.; Yang, W.M.; Arfuso, F.; Um, J.Y.; Kumar, A.P.; Bian, J.; Sethi, G.; Ahn, K.S. Formononetin-induced oxidative stress abrogates the activation of STAT3/5 signaling axis and suppresses the tumor growth in multiple myeloma preclinical model. *Cancer Lett.* 2018, 431, 123–141. [CrossRef]

81. Li, F.; Zhang, J.; Arfuso, F.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Kumar, A.P.; Ahn, K.S.; Sethi, G. NF-kappaB in cancer therapy. *Arch. Toxicol.* 2015, 89, 711–731. [CrossRef]

82. Manu, K.A.; Shanmugam, M.K.; Ramachandran, L.; Li, F.; Fong, C.W.; Kumar, A.P.; Tan, P.; Sethi, G. First evidence that gamma-tocotrienol inhibits the growth of human gastric cancer and chemosensitizes it to capecitabine in a xenograft mouse model. *Clin. Cancer Res.* 2012, 18, 2220–2229. [CrossRef] [PubMed]

83. Sethi, G.; Shanmugam, M.K.; Ramachandran, L.; Kumar, A.P.; Tergaonkar, V. Multifaceted link between cancer and inflammation. *Biosci. Rep.* 2012, 32, 1–15. [CrossRef]

84. Li, F.; Sethi, G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. *Biochim. Biophys. Acta* 2010, 1805, 167–180.

85. Sethi, G.; Tergaonkar, V. Potential pharmacological control of the NF-kappaB pathway. *Trends Pharmacol. Sci.* 2009, 30, 313–321. [CrossRef] [PubMed]

86. Ahn, K.S.; Sethi, G.; Aggarwal, B.B. Nuclear factor-kappa B: From clone to clinic. *Curr. Mol. Med.* 2007, 7, 619–637. [CrossRef] [PubMed]

87. Liu, L.; Ahn, K.S.; Shanmugam, M.K.; Wang, H.; Shen, H.; Arfuso, F.; Chinnathambi, A.; Alharbi, S.A.; Chang, Y.; Sethi, G.; et al. Oleuropein induces apoptosis via abrogating NF-kappaB activation cascade in estrogen receptor-negative breast cancer cells. *J. Cell. Biochem.* 2018. [CrossRef]

88. Puar, Y.R.; Shanmugam, M.K.; Fan, L.; Arfuso, F.; Sethi, G.; Tergaonkar, V. Evidence for the Involvement of the Master Transcription Factor NF-kappaB in Cancer Initiation and Progression. *Biomedicines* 2018, 6, 82. [CrossRef]

89. Chai, E.Z.; Siveen, K.S.; Shanmugam, M.K.; Arfuso, F.; Sethi, G. Analysis of the intricate relationship between chronic inflammation and cancer. *Biochem. J.* 2015, 468, 1–15. [CrossRef]

90. Shanmugam, M.K.; Ahn, K.S.; Lee, J.H.; Kannaiyan, R.; Mustafa, N.; Manu, K.A.; Siveen, K.S.; Sethi, G.; Chng, W.J.; Kumar, A.P. Celastrol Attenuates the Invasion and Migration and Augments the Anticancer Effects of Bortezomib in a Xenograft Mouse Model of Multiple Myeloma. *Front. Pharmacol.* 2018, 9, 365. [CrossRef]

91. Manu, K.A.; Shanmugam, M.K.; Ramachandran, L.; Li, F.; Siveen, K.S.; Chinnathambi, A.; Zayed, M.E.; Alharbi, S.A.; Arfuso, F.; Kumar, A.P.; et al. Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-kappaB signaling cascade in gastric cancer. *Cancer Lett.* 2015, 363, 28–36. [CrossRef] [PubMed]

92. Li, F.; Shanmugam, M.K.; Siveen, K.S.; Wang, F.; Ong, T.H.; Loo, S.Y.; Swamy, M.M.; Mandal, S.; Kumar, A.P.; Goh, B.C.; et al. Garcinol sensitizes human head and neck carcinoma to cisplatin in a xenograft mouse model despite downregulation of proliferative biomarkers. *Oncotarget* 2015, 6, 5147–5163. [CrossRef] [PubMed]

93. DiGiovanni, J. Multistage carcinogenesis in mouse skin. *Pharmacol. Ther.* 1992, 54, 63–128. [CrossRef]

94. Kleiner, H.E.; Vulimiri, S.V.; Reed, M.J.; Überecken, A.; DiGiovanni, J. Role of cytochrome P450 1a1 and 1b1 in the metabolic activation of 7,12-dimethylbenz[a]anthracene and the effects of naturally occurring furanocoumarins on skin tumor initiation. *Chem. Res. Toxicol.* 2002, 15, 226–235. [CrossRef] [PubMed]

95. Thiery, J.P. Epithelial-mesenchymal transitions in tumour progression. *Nat. Rev. Cancer* 2002, 2, 442–454. [CrossRef] [PubMed]

96. Lo, H.C.; Zhang, X.H. EMT in Metastasis: Finding the Right Balance. *Dev. Cell* 2018, 45, 663–665. [CrossRef] [PubMed]
97. Buiatti, E.; Palli, D.; Decarli, A.; Amadori, D.; Avellini, C.; Bianchi, S.; Biserni, R.; Cipriani, F.; Cocco, P.; Giacosa, A.; et al. A case-control study of gastric cancer and diet in Italy. *Int. J. Cancer* 1989, 44, 611–616. [CrossRef] [PubMed]

98. Ramon, J.M.; Serra, L.; Cerdo, C.; Oromi, J. Dietary factors and gastric cancer risk. A case-control study in Spain. *Cancer* 1993, 71, 1731–1735. [CrossRef]

99. Gonzalez, C.A.; Pera, G.; Agudo, A.; Bueno-de-Mesquita, H.B.; Ceroti, M.; Boeing, H.; Schulz, M.; Del Giudice, G.; Plebani, M.; Carneiro, F.; et al. Fruit and vegetable intake and the risk of stomach and oesophagus adenocarcinoma in the European Prospective Investigation into Cancer and Nutrition (EPIC-EURGAST). *Int. J. Cancer* 2006, 118, 2559–2566. [CrossRef] [PubMed]

© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).